CSBio CSBio

X
[{"orgOrder":0,"company":"Immutep","sponsor":"University Hospital Pilsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Announces the Start of an Investigator-Initiated\n Phase II Study in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Starts Phase II Study of ArtemiC to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"MGC Pharmaceuticals"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharmaceuticals Expands ArtemiC\u2122 Phase II Clinical Trial on COVID-19 Patients in Israel and India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"MGC Pharmaceuticals"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharmaceuticals Provides ArtemiCTM Phase II Clinical Trial Results Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"MGC Pharmaceuticals"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Malta Enerprises","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"$3.7 million","newsHeadline":"MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"MGC Pharmaceuticals"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EnGeneIC Publishes The COVID-EDV Vaccine\u2019s Novel Mechanism of Action in A Leading Immunology Journal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"EnGeneIC"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE Anti-Infectives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Recce Pharmaceuticals"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Receives European Patent on Drug Composition to Treat Travelers\u2019 Diarrhea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Immuron"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"COPD Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ENA Respiratory"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ENA Respiratory"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Blue Knight","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENA Respiratory Selected for BLUE KNIGHT\u2122 to Accelerate Development of Pan-Antiviral Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ENA Respiratory"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ENA Respiratory"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ENA Respiratory"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$8.1 million","upfrontCash":"Undisclosed","newsHeadline":"ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ENA Respiratory"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ENA Respiratory"},{"orgOrder":0,"company":"Island Pharmaceuticals","sponsor":"State University of New York","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Island Pharmaceuticals Granted Key Patent for ISLA-101 in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Island Pharmaceuticals"},{"orgOrder":0,"company":"Ampion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ampion"},{"orgOrder":0,"company":"CSL","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"CSL"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            INNA-051 is a potent TLR2/6 agonist that is delivered using a convenient nasal spray to target the preferential site of initial replication of viral respiratory infections.

            Lead Product(s): INNA-051

            Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funding will support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator for the prevention of complications associated with respiratory viral infections in at-risk populations.

            Lead Product(s): INNA-051

            Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: U.S. Department of Defense

            Deal Size: $8.1 million Upfront Cash: Undisclosed

            Deal Type: Funding August 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            CSL

            Contact Supplier
            • Deals

            Details:

            Under the terms of agreement, CSL Seqirus will deliver an H5N8 A/Astrakhan virus vaccine candidate and will then sponsor a subsequent Phase 2 clinical trial to evaluate the candidate along with CSL Seqirus’ proprietary adjuvant MF59®.

            Lead Product(s): H5N8 A/Astrakhan Virus Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding August 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Recce® 327 is an anti-infective compound which can be administered for intravenous, topical, nasal, oral and inhaled use. Its universal mechanism of action has a patented ability to continuously kill bacteria without tendency for the emergence of resistance.

            Lead Product(s): R327

            Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            INNA-051 is a broad-spectrum antiviral immunomodulatory nasal spray under clinical development for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of severe complications.

            Lead Product(s): INNA-051

            Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This paper illustrates that the COVID-EDV vaccine is a fundamental change in thinking on how to produce an effective and inexpensive vaccine and has broad-reaching ramifications for vaccinology.

            Lead Product(s): COVID-EDV

            Therapeutic Area: Infections and Infectious Diseases Product Name: COVID-EDV

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 31, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            INNA-051 is a potent innate immune TLR2/6 agonist. It is currently in clinical development for self-administered intranasal delivery to target the primary entry site of viral respiratory infections as most respiratory viruses, including SARS-CoV-2 and influenza.

            Lead Product(s): INNA-051

            Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: U.S. Department of Defense

            Deal Size: $4.3 million Upfront Cash: Undisclosed

            Deal Type: Funding January 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Pre-clinical research demonstrates that INNA-051 has pan-antiviral potential with efficacy against a variety of respiratory viruses, including SARS-CoV-2, influenza, and the common cold rhinovirus.

            Lead Product(s): INNA-051

            Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Blue Knight

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, a potent innate immune TLR2/6 agonist, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections.

            Lead Product(s): INNA-051

            Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 15, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The partnership adds INNA-051 to the COPD Foundation’s COPD360Net® pipeline and will utilize its global network of accredited centres, scientific expertise, and patient investigators to optimize and accelerate the clinical development program.

            Lead Product(s): INNA-051

            Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: COPD Foundation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY